53 related articles for article (PubMed ID: 14695607)
1. A tetraguanidinium ligand binds to the surface of the tetramerization domain of protein P53.
Salvatella X; Martinell M; Gairí M; Mateu MG; Feliz M; Hamilton AD; De Mendoza J; Giralt E
Angew Chem Int Ed Engl; 2004 Jan; 43(2):196-8. PubMed ID: 14695607
[No Abstract] [Full Text] [Related]
2. Structure of the human p53 core domain in the absence of DNA.
Wang Y; Rosengarth A; Luecke H
Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):276-81. PubMed ID: 17327663
[TBL] [Abstract][Full Text] [Related]
3. On the role of flexibility in protein-ligand interactions: the example of p53 tetramerization domain.
Gordo S; Martos V; Vilaseca M; Menéndez M; de Mendoza J; Giralt E
Chem Asian J; 2011 Jun; 6(6):1463-9. PubMed ID: 21626703
[TBL] [Abstract][Full Text] [Related]
4. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
[TBL] [Abstract][Full Text] [Related]
5. Synthetic ligands able to interact with the p53 tetramerization domain. Towards understanding a protein surface recognition event.
Martinell M; Salvatella X; Fernández-Carneado J; Gordo S; Feliz M; Menéndez M; Giralt E
Chembiochem; 2006 Jul; 7(7):1105-13. PubMed ID: 16795116
[TBL] [Abstract][Full Text] [Related]
6. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin.
De Grandis V; Bizzarri AR; Cannistraro S
J Mol Recognit; 2007; 20(4):215-26. PubMed ID: 17703463
[TBL] [Abstract][Full Text] [Related]
7. Modeling the interaction between the N-terminal domain of the tumor suppressor p53 and azurin.
Taranta M; Bizzarri AR; Cannistraro S
J Mol Recognit; 2009; 22(3):215-22. PubMed ID: 19140135
[TBL] [Abstract][Full Text] [Related]
8. Forewarned is four-armed.
Surridge C
Nature; 1994 Dec; 372(6505):482. PubMed ID: 7984245
[TBL] [Abstract][Full Text] [Related]
9. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association.
Sachchidanand ; Resnick-Silverman L; Yan S; Mutjaba S; Liu WJ; Zeng L; Manfredi JJ; Zhou MM
Chem Biol; 2006 Jan; 13(1):81-90. PubMed ID: 16426974
[TBL] [Abstract][Full Text] [Related]
10. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T; Kato S; Otsuka K; Watanabe G; Kumabe T; Tominaga T; Yoshimoto T; Ishioka C
Oncogene; 2005 Oct; 24(46):6976-81. PubMed ID: 16007150
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
12. Binding of RNA to p53 regulates its oligomerization and DNA-binding activity.
Yoshida Y; Izumi H; Torigoe T; Ishiguchi H; Yoshida T; Itoh H; Kohno K
Oncogene; 2004 May; 23(25):4371-9. PubMed ID: 15064727
[TBL] [Abstract][Full Text] [Related]
13. Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR.
Petros AM; Gunasekera A; Xu N; Olejniczak ET; Fesik SW
FEBS Lett; 2004 Feb; 559(1-3):171-4. PubMed ID: 14960327
[TBL] [Abstract][Full Text] [Related]
14. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.
Stros M; Muselíková-Polanská E; Pospísilová S; Strauss F
Biochemistry; 2004 Jun; 43(22):7215-25. PubMed ID: 15170359
[TBL] [Abstract][Full Text] [Related]
15. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure.
Nomura T; Kamada R; Ito I; Chuman Y; Shimohigashi Y; Sakaguchi K
Biopolymers; 2009 Jan; 91(1):78-84. PubMed ID: 18781628
[TBL] [Abstract][Full Text] [Related]
16. Computational screening and design of S100B ligand to block S100B-p53 interaction.
Whitlow JL; Varughese JF; Zhou Z; Bartolotti LJ; Li Y
J Mol Graph Model; 2009; 27(8):969-77. PubMed ID: 19324580
[TBL] [Abstract][Full Text] [Related]
17. Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain.
Pivonková H; Brázdová M; Kaspárková J; Brabec V; Fojta M
Biochem Biophys Res Commun; 2006 Jan; 339(2):477-84. PubMed ID: 16300733
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
Xu H; Tai J; Ye H; Kang CB; Yoon HS
Biochem Biophys Res Commun; 2006 Mar; 341(4):938-44. PubMed ID: 16455050
[TBL] [Abstract][Full Text] [Related]
19. Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability.
Poon GM; Brokx RD; Sung M; Gariépy J
J Mol Biol; 2007 Jan; 365(4):1217-31. PubMed ID: 17113101
[TBL] [Abstract][Full Text] [Related]
20. Cooperative binding of tetrameric p53 to DNA.
Weinberg RL; Veprintsev DB; Fersht AR
J Mol Biol; 2004 Aug; 341(5):1145-59. PubMed ID: 15321712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
